Global Leukemia Market - Upcoming Trends, Growth Drivers and Challenges – Forecast to -2018-2025
Summary -
A new market
study, titled “Global Leukemia Market
- Upcoming Trends,
Growth Drivers and Challenges – Forecast to -2018-2025” has been featured on WiseGuyReports.
Leukemia is one of
the most deliberating cancer types which substantially contributes to the
global disease burden and mortality rates. Leukemia is a type of blood cancer.
It typically originates in the bone marrow and results in the abnormality in
leucocytes. The major types of leukemias include – acute lymphocytic leukemia
(ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and
chronic myeloid leukemia (CML).
Prevalence of
leukemia is quite high globally. According to GLOBOCAN 2020, leukemia ranked
the 11th most common cancer type affecting the population globally which an
incidence of 0.35 million in 2012 and its incidence is expected to rise to 0.41
million by 2020. Increasing cancer prevalence, improving treatment rates, the
rise in standards of healthcare infrastructure especially in merging nations,
the emergence of combination therapeutic options for treatment of leukemia
types and the scope of drug re-positioning formed the impetus for the market
growth in recent years and will also propel the market in the forecast period.
(2018-2025)
The global market
for leukemia was worth $XX billion in 2017 and is forecasted to reach $XX
billion by 2025, growing at a CAGR of XX%.
Global Leukemia
Market – Market Dynamics
The demand for leukemia
therapeutics will expand at a notable rate in the foreseeable future primarily
driven by the product approval of repositioned drugs, the concept of
application for expanded indication approvals for the existing drugs and advent
of novel therapeutics; high practice of off-label prescriptions, increase in
prevalence population; high R&D investments and rise in healthcare
standards especially on emerging countries. The market is anticipated to be
restrained by high costs associated with drug development. adverse side-effects
associated with chemotherapeutic options and inadequate access to healthcare in
rural regions of emerging countries. However, favorable public initiatives and
the emergence of innovative therapeutics are anticipated to create promising
growth opportunities for the market players in the leukemia market across the
globe.
Overall the key
market drivers include –
Increase in
Prevalence of Leukemia Sub-types
Robust Pipeline with
Potential Late-Stage Molecules
Favorable Special
Regulatory Designations for Drugs
High R&D
Investments For Drug Discovery
Increase in
Diagnosis and Treatment Seeking Population
Overall the key
market restraints include –
Complex Disease
Prognosis
Adverse Effects of
Therapeutic Options
The dearth of
Healthcare Professionals in Emerging Countries
Inadequate
Reimbursement and Treatment Access
Market Trends and
Opportunities
High focus on
Combination Therapies and Drug-Repositioning
The emergence of
Targeted Therapies
Global Leukemia
Market – Segment Analysis (By Disease Type)
Based on disease
type the global market for Leukemia are broadly segmented- namely acute
lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, and
chronic myeloid leukemia.
The market currently
is dominated by chronic lymphocytic leukemia therapeutics. In the forecast
period, the market the market for acute lymphocytic leukemia and chronic
myeloid leukemia are anticipated to contribute a notable share of the overall
leukemia therapeutics.
Global Leukemia
Market – Geographical Analysis
The global market
for leukemia therapeutics is segmented into North America, Europe, Asia
Pacific, South America and the Middle East and Africa. North America
contributed the highest market followed by Europe in 2017. High disease
awareness, favorable reimbursement, high healthcare access, advanced healthcare
infrastructure, high disease prevalence and favorable government policies and
initiatives are key factors for substantial market size in these regions.
In terms of growth
rate, APAC is anticipated to post highest growth rate in forecast period owing
to the development of the healthcare infrastructure in especially contributed
by China and India. Rising investments for R&D activities are projected to
encourage the growth of the leukemia therapeutics market in APAC region. In
addition, increasing healthcare expenditures, rising prevalence of leukemia are
also anticipated to fuel the market’s growth in the forecast period.
Global Leukemia Market
Global Leukemia
Market – Competitive Analysis
The competitive
landscape for Leukemia therapeutics is concentrated with a limited number of
key vendors contributing to substantial market share. The remaining minor share
is contributed by multiple international as well as local vendors manufacturing
low-cost generic chemotherapeutic drugs.
The key vendors are
continually focusing to strengthen its market competitiveness by the high focus
of R&D, innovation of novel combination therapeutics. Companies are also
increasingly focusing on patient assistance programs and drug repositioning to
gain the competitive edge and improve market entrenchment.
Some of the major
companies operating in the global leukemia market are – AbbVie, Novartis,
Pfizer, Bristol-Myers Squibb Company, Genzyme, Celgene, GlaxoSmithKline,
Cephalon, Eisai and Teva Pharmaceuticals.
Scope of the Report
The report covers
the factors impacting the market, Porter 5 Forces, Market Share Analysis,
by-therapy analysis, by disease analysis, and company profiles. Global leukemia
market is segmented based on the disease type as acute lymphocytic leukemia,
chronic lymphocytic leukemia, acute myeloid leukemia, and chronic myeloid
leukemia. Based on therapy type market is categorized as – targeted/immune
therapies and chemotherapeutics. Based on geography the market is segmented
into – North America, South America, Europe, Asia Pacific and the Middle East
and Africa.
The report profiles
the following companies – AbbVie, Novartis, Pfizer, Bristol-Myers Squibb
Company, Genzyme, Celgene, Glaxosmithkline, Cephalon, Eisai and Teva
Pharmaceuticals, Ambit Biosciences, Genmab A/S and Talon Therapeutics/
Why Purchase the
report?
Visualize the
composition of the leukemia market across each indication, in terms of therapy
type and disease type, highlighting the key commercial assets and players.
Identify commercial
opportunities in leukemia by analyzing trends and co-development deals.
This is the most
comprehensive study on leukemia market to date.
Excel data sheet
with thousands of data points of the leukemia market – level 4/5 segmentation.
PDF report with the
most relevant analysis cogently put together after exhaustive qualitative
interviews and in-depth market study.
Product mapping in
excel for the key leukemia drugs of all major market players.
Target Audience
Raw Material
Suppliers/ Buyers
Product Suppliers/
Buyers
Industry
Investors/Investment Bankers
Education &
Research Institutes
Research
Professionals
Emerging Companies
Manufacturer
FOR MORE DETAILS : https://www.wiseguyreports.com/reports/3792271-global-leukemia-market-size-trends-competitive-analysis-market
About Us:
Wise Guy Reports is part of the Wise Guy Research
Consultants Pvt. Ltd. and offers premium progressive statistical surveying,
market research reports, analysis & forecast data for industries and governments
around the globe.
Contact Us:
NORAH
TRENT
Ph: +162-825-80070
(US)
Ph: +44 2035002763 (UK)
Comments
Post a Comment